U.S. markets closed
  • S&P 500

    +61.35 (+1.49%)
  • Dow 30

    +360.68 (+1.06%)
  • Nasdaq

    +304.99 (+2.32%)
  • Russell 2000

    +53.68 (+2.47%)
  • Crude Oil

    +1.69 (+2.65%)
  • Gold

    +20.00 (+1.10%)
  • Silver

    +0.47 (+1.72%)

    +0.0062 (+0.51%)
  • 10-Yr Bond

    -0.0330 (-1.98%)

    +0.0050 (+0.36%)

    -0.0870 (-0.08%)

    -2,161.12 (-4.21%)
  • CMC Crypto 200

    +39.77 (+2.93%)
  • FTSE 100

    +80.28 (+1.15%)
  • Nikkei 225

    +636.46 (+2.32%)

Biotech Breaking Out

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

HENDERSON, NV / ACCESSWIRE / January 16, 2019 / Since hitting its lows on Dec. 26, biotech has soared more than 20 percent as of Friday, and was posting its best start to a year since 2012. Here are a few in the sector that we like.

A biotech we like a lot is, Endonovo Therapeutics, Inc. (ENDV). The company has several non-invasive therapies tackling everything from pain management to degenerative joint diseases. The company just announced a deal that will add up to $10 million in working capital to their balance sheet which could amplify the company's already rapid growth. Do your due diligence on ENDV, it may be the next big winner in the biotech industry.

We are highlighting: Endonovo Therapeutics, Inc. (ENDV), Matinas BioPharma Holdings, Inc. (MTNB), MannKind Corporation (MNKD), Rexahn Pharmaceuticals, Inc. (RNN), and Cronos Group (CRON).

The global market for non-opioid pain treatment totaled $9.9 billion in 2017 and is estimated to reach $22.6 billion by 2022, growing at a CAGR of 18.0% for the period of 2017-2022. The aforementioned Endonovo Therapeutics, Inc. (ENDV) (Market Cap: $12.602M, Share Price: $0.029), a commercial-stage developer of non-invasive wearable Electroceuticals™ Therapies, has developed a therapy that could help lessen the pain without the kinds of side effects many other opioid alternatives have. Their non-invasive easy to use ORTHOHALO™ device delivers targeted Pulsed ElectroMagnetic Field (tPEMF) therapies to reduce pain and enhance post-surgical recovery, naturally. Its patented non-pharmacologic process uses proprietary technology to reduce pain, swelling, and inflammation.

The company just released a shareholder letter, in it there is a list of the company's latest accomplishments. The list below is pretty impressive and is a big reason why the company is starting a major rally.

Highlights include:

  • Signing two marketing agreements with well-established medical device sales organizations

  • Establishment and expansion of a rapidly growing sales department

  • The completion of the purchase price to the seller of the SofPulse Technology

  • The new Roma medical device is on schedule for release in Q1 of 2019

ENDV also announced an agreement with Azure Capital that will bring the company up to $10 Million for general corporate purposes, including working capital. This is a major development that could expedite the company's growth.

Now is the time to start your research on ENDV.


Matinas BioPharma Holdings, Inc. (MTNB) (Market Cap: $110.858M, Share Price: $0.9864) announced they have signed an agreement with an undisclosed top global pharmaceutical company aimed to evaluate synergistic effects of Matinas' lipid-nano-crystal ("LNC") platform delivery technology with their partner's nucleic acid polymer technology.


MannKind Corporation (MNKD) (Market Cap: $248.19M, Share Price: $1.38) recently held an Investor call, the company's stock is performing well since.


Rexahn Pharmaceuticals, Inc. (RNN) (Market Cap: $44.65M, Share Price: $1.19) announced that it will present updated preliminary safety and efficacy data from the ongoing Phase 2a clinical trial of RX-3117 in combination with ABRAXANE® in first-line metastatic pancreatic cancer patients at the 2019 American Society of Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Symposium being held January 17-19, 2019.


Cronos Group, Inc. (CRON) (Market Cap: $2.329B, Share Price: $13.05) has received over $14 billion in investment dollars from Altria for a 45% stake in the company.

Legal Disclaimer:

This article was written by Regal Consulting, LLC ("Regal Consulting"). Regal consulting has agreed to receive 3 million restricted 144 shares as a signing bonus, and additionally receive $4,000 cash per month, and 1 million restricted 144 shares per month starting 8/23/18, this is a twelve-month agreement, and can be canceled at any time by the issuer ENDV. All payments were made directly by Endonovo Therapeutics, Inc. to Regal Consulting, LLC. to provide investor relations services, of which this article is a part of. Regal Consulting also paid one thousand dollars cash to microcapspeculators.com to distribute this article. Regal Consulting may have a position in the securities mentioned in this article at the time of publication, and may increase or decrease its position without notice. This article is based on public information and the opinions of Regal Consulting. ENDV was given an opportunity to edit this article. This article contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any results predicted herein. Regal Consulting is not registered with any financial or securities regulatory authority, and does not provide or claim to provide investment advice.

http://www.regalconsultingllc.com/full legal disclaimer/

Microspeculators.com Full Legal Disclaimer Click Here.

Contact Information:

Company Name: Microcap Speculators

Contact Person: Media Manager

Email: info@microcapspeculators.com

Phone: 1-702-720-6310

Country: United States

Website: http://microcapspeculators.com/

SOURCE: Microcap Speculators